Global Glaucoma Therapeutics Market 2017-2021

緑内障治療薬の世界市場2017-2021:プロスタグランジン類似体、ベータ遮断薬、アルファ作動薬、炭酸脱水酵素阻害薬、その他

◆タイトル:Global Glaucoma Therapeutics Market 2017-2021
◆商品コード:IRTNTR15263
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年10月18日
◆ページ数:97
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・バイオ・製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、緑内障治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、緑内障治療薬の世界市場規模及び予測、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は緑内障治療薬の世界市場が2017-2021年期間中に年平均3.81%成長すると予測しています。当レポート上に記載されている主な企業は、Allergan、Pfizer、Novartis、Merck等です。

About Glaucoma Therapeutics
Glaucoma is an ophthalmic disorder that damages the optic nerves in the eyes. The disease is associated with elevated IOP and over time leads to the damage of the optic nerves, by destroying their cell bodies and delicate fibers. This can lead to partial loss of vision or complete blindness. Increased IOP is majorly due to the build-up of aqueous humor, which circulates in the front of an eye.

Technavio’s analysts forecast the global glaucoma therapeutics market to grow at a CAGR of 3.81% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global glaucoma therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Glaucoma Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Allergan
• Pfizer
• Novartis
• Merck

[Other prominent vendors]
• Bayer HealthCare
• Akorn
• Bausch & Lomb
• Santen Pharmaceutical
• Teva Pharmaceutical
• VISTAKON

[Market driver]
• Increasing geriatric population leading to higher prevalence rate of glaucoma
• For a full, detailed list, view our report

[Market challenge]
• Growing popularity of alternative treatment options
• For a full, detailed list, view our report

[Market trend]
• Rising investment in R&D activities
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: RESEARCH METHODOLOGY

PART 03: INTRODUCTION
• Market outline

PART 04: MARKET LANDSCAPE
• Market overview
• Five forces analysis

PART 05: PIPELINE LANDSCAPE

PART 06: MARKET SEGMENTATION BY DRUG CLASS
• Global glaucoma therapeutics market by prostaglandin analogs
• Global glaucoma therapeutics market by beta blockers
• Global glaucoma therapeutics market by alpha agonists
• Global glaucoma therapeutics market by carbonic anhydrase inhibitors
• Global glaucoma therapeutics market by others

PART 07: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – market size and forecast
• EMEA – market size and forecast
• APAC – market size and forecast
• Market opportunity

PART 08: DECISION FRAMEWORK

PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
• Competitive scenario

PART 12: KEY VENDOR ANALYSIS
• Allergan
• Pfizer
• Novartis
• Merck
• Other prominent vendors

PART 13: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Global ophthalmic disorder treatment market
Exhibit 02: Types of glaucoma
Exhibit 03: Factors leading to angle-closure glaucoma
Exhibit 04: Types of secondary glaucoma
Exhibit 05: Global glaucoma therapeutics market snapshot
Exhibit 06: Global glaucoma therapeutics market 2016-2021 ($ millions)
Exhibit 07: Five forces analysis
Exhibit 08: Major pipeline molecules by vendors
Exhibit 09: Key clinical trials
Exhibit 10: Global glaucoma therapeutics market by drug class ($ millions)
Exhibit 11: Global glaucoma therapeutics market by drug class 2016-2021
Exhibit 12: Global glaucoma therapeutics market by prostaglandin analogs 2016-2021 ($ millions)
Exhibit 13: Advantages and disadvantages of prostaglandin analogs present in global glaucoma therapeutics market
Exhibit 14: Global glaucoma therapeutics market by beta blockers 2016-2021 ($ millions)
Exhibit 15: Common beta blockers used as glaucoma therapeutics
Exhibit 16: Global glaucoma therapeutics market by alpha agonists 2016-2021 ($ millions)
Exhibit 17: Common alpha agonists used for glaucoma treatment
Exhibit 18: Global glaucoma therapeutics market by carbonic anhydrase inhibitors 2016-2021 ($ millions)
Exhibit 19: Common carbonic anhydrase inhibitors used for glaucoma treatment
Exhibit 20: Global glaucoma therapeutics market by others 2016-2021 ($ millions)
Exhibit 21: Cholinergic agents used for glaucoma treatment
Exhibit 22: Americas – market size and forecast
Exhibit 23: Regional comparison
Exhibit 24: Americas – market size and forecast
Exhibit 25: Americas – Year over year growth
Exhibit 26: A snapshot on eye diseases in US 2014 and 2030
Exhibit 27: Snapshot of economic and healthcare expenditure of US 2014-2015
Exhibit 28: Economic and healthcare snapshot of Canada
Exhibit 29: Top three countries in Americas
Exhibit 30: Economic and healthcare snapshot of Europe 2014
EMEA – market size and forecast
Exhibit 31: EMEA – year-over-year growth
Exhibit 32: Medication scenario for glaucoma in Europe
Exhibit 33: Top three countries in EMEA
Exhibit 34: APAC – market size and forecast
Exhibit 35: APAC – year-over-year growth
Exhibit 36: Top three countries in APAC
Exhibit 37: World population by age group 2015 and 2050
Exhibit 38: Percentage of population aged 60 and above by region 2015 and 2050
Exhibit 39: Non-therapeutic glaucoma treatment
Exhibit 40: Side effects of the commonly used glaucoma medications
Exhibit 41: Need of new drug delivery systems
Exhibit 42: Novel efforts in glaucoma therapeutics market
Exhibit 43: Competitive structure analysis of global glaucoma therapeutics market 2016
Exhibit 44: Allergan: Key highlights
Exhibit 45: Allergan: Strength assessment
Exhibit 46: Allergan: Strategy assessment
Exhibit 47: Allergan: Opportunity assessment
Exhibit 48: Pfizer: Key highlights
Exhibit 49: Pfizer: Strength assessment
Exhibit 50: Pfizer: Strategy assessment
Exhibit 51: Pfizer: Opportunity assessment
Exhibit 52: Novartis: Key highlights
Exhibit 53: Novartis: Strength assessment
Exhibit 54: Novartis: Strategy assessment
Exhibit 55: Novartis: Opportunity assessment
Exhibit 56: Merck: Key highlights
Exhibit 57: Merck: Strength assessment
Exhibit 58: Merck: Strategy assessment
Exhibit 59: Merck: Opportunity assessment



【掲載企業】

Allergan, Pfizer, Novartis, Merck, Bayer HealthCare, Akorn, Bausch & Lomb, Santen Pharmaceutical, Teva Pharmaceutical, and VISTAKON.


★調査レポート[緑内障治療薬の世界市場2017-2021:プロスタグランジン類似体、ベータ遮断薬、アルファ作動薬、炭酸脱水酵素阻害薬、その他] (Global Glaucoma Therapeutics Market 2017-2021 / IRTNTR15263)販売に関する免責事項
[緑内障治療薬の世界市場2017-2021:プロスタグランジン類似体、ベータ遮断薬、アルファ作動薬、炭酸脱水酵素阻害薬、その他] (Global Glaucoma Therapeutics Market 2017-2021 / IRTNTR15263)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆